knowledge -WSS

knowledge

author：entertainment 2025-09-27 23:12:17 - browse：65

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： How to convince healthy people to buy insurance

WSS

The stability of $0 premiums in Medicare Advantage

Medicare must police algorithms in Medicare Advantage, Dems say

Lawsuit highlights wrinkle for disputes over surprise medical bills

Key Senate panel to consider PBM, drug pricing reform package

Medicare proceeds with plan to claw back hospital funds

Humans aren't the only ones with an imagination. Rats have it too

hotspot

knowledge

focus

BioMarin wins approval for gene therapy to treat hemophilia A

What we owe ALS patients — and why one company fell short

In age of alternative facts, a scholarly course on calling out crap

Experts study whether long Covid risk adds up with each reinfection

What does generative AI mean for health care? We asked experts

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Moonlake's readout produced a cash windfall. Risks remain

Study points to new risk in gene therapy death of Terry Horgan

DIEP, the 'gold standard' of breast reconstruction, is under threat

What we owe ALS patients — and why one company fell short

leisure time

With Roe v Wade overturned, abortion providers work to adapt

Key Senate panel to consider PBM, drug pricing reform package

The United States is paying nearly triple for new Covid vaccines

New oral drug delivery patch is modeled after octopus tentacles

Lung cancer screening guidelines updated for cigarette smokers

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Wikipedia

hotspot

Wikipedia

knowledge